The Loyalty State Has Supply Chains

The governing style on display is not quite isolationism, protectionism, or transactional diplomacy. It is a more improvisational compound: use every lever at once, then treat the resulting machinery as an extension of a personal negotiating posture. Tariffs are national-security policy; an old territorial dispute becomes potential leverage over an ally; a health investigation is arranged around a politically convenient starting date. The coherence lies less in doctrine than in the conviction that all institutions should be available for pressure. The trouble is that supply chains, treaties, and chronology are notoriously poor at taking instructions.

Consider the two most revealing collisions. Washington’s new polysilicon measures are meant to fortify a strategically important domestic material used in solar panels and semiconductors, yet they may help put a Tennessee producer’s future in doubt. Meanwhile, Donald Trump’s suggestion that the US position on the Falklands might be reviewed has given Argentina’s Javier Milei an opening to escalate pressure on an offshore oil project—and raised alarms in Britain. The polysilicon report and the Falklands account describe different arenas, but the same operating principle: ambiguity is no longer a diplomatic condition to manage; it is an instrument to brandish.

There is a certain administrative romance to this. Everything becomes negotiable, provided one has not yet bothered to learn which parts are load-bearing. But national power is not a television set: a tariff can hit a domestic factory, a territorial hint can change investment calculations, and an inquiry into vaccines can stumble over the inconvenient fact that the vaccine rollout began under the very administration whose political inheritance it wishes to protect. The state, sadly for the dramaturgically minded, maintains a calendar.

Wacker Chemie is weighing the future of its Charleston, Tennessee, polysilicon plant after reportedly losing its final two customers following Washington’s new measures. About 600 jobs are implicated, though no closure has been announced. That conditional matters: the rules take effect in December and can still be amended. Still, this is a peculiar way to announce industrial revival—by making the prospective beneficiary wonder whether it has become surplus equipment. The Next Web’s report, citing Reuters, says Wacker and Hemlock Semiconductor are the only remaining US producers.

The apparent flaw is almost beautiful in its bureaucratic severity. The August proclamation sets a 15 percent duty on most imported polysilicon and derivatives, alongside price floors, but its coverage reportedly extends to downstream ingots, wafers, cells, and panels regardless of whether the polysilicon inside was made in America. Wacker says the policy, as written, does not effectively support use of US-made polysilicon. American material reportedly costs roughly four times Chinese material; policy has therefore contrived to make the domestic input expensive and to complicate the products that might absorb it. Read the underlying account here.

This is not an argument against strategic industrial policy. It is an argument for noticing the industrial part. US polysilicon output reportedly fell from about half of global production in 2005 to under 2 percent by 2024. If the goal is to preserve capacity relevant to chips and defence systems, losing one of two remaining producers would be less a hard-nosed security achievement than an own goal executed with a tariff schedule. The administration can reportedly distinguish US-made material from imports before December. The question is whether it sees policy as a machine for building capacity—or merely a machine for displaying resolve.

Milei has responded to the perceived opening with the practiced instincts of a leader facing domestic pressure and a national symbol with unusually durable electoral properties. He has proposed tougher penalties for companies involved in the Sea Lion deep-sea oil project, which lies north of the Falklands in waters administered by the islands but claimed by Argentina. The proposed sanctions could reach suppliers, shareholders, and directors, and could bar involved companies from operating in Argentina; they still require legislation. Al Jazeera’s first report lays out the proposal and its limits.

Trump has not endorsed Argentina’s sovereignty claim. He has said the US position could be reviewed, while the reporting describes a history of Washington recognizing Britain’s de facto administration without formally resolving sovereignty. That distinction will not soothe London, which has reaffirmed its commitment to the islands and points to the 2013 referendum, in which 1,513 of 1,517 voters backed remaining a British overseas territory. Nor is this an abstraction for Argentina: the 1982 war killed 649 Argentine and 255 British service members. The fuller account is here.

The practical consequence of even a limited US shift may be less a transfer of sovereignty than an increase in uncertainty. Analysts cited by Al Jazeera say American backing would not compel Britain to negotiate, nor let Buenos Aires physically halt production. It could, however, complicate investment around Sea Lion, where drilling is expected in coming months and production is planned for 2028. That is how great-power leverage often operates in the real world: not as a cavalry charge across the South Atlantic, but as a new risk calculation on an insurer’s spreadsheet. For Milei, that may be politically useful; for islanders and investors, it is another reminder that their future can become collateral in a quarrel elsewhere.

The reported HHS-Defense Department inquiry into whether service members died from COVID-19 vaccines is still an inquiry, not a finding. Army doctor Theresa Long reportedly told a deposition that she was examining 2,544 unverified VAERS death reports among service members and expected to finish within a year. VAERS reports do not themselves establish causation; the supplied reporting provides neither the investigation’s methodology nor evidence that vaccination caused any reported death. Those are not fussy caveats. They are the difference between investigation and insinuation. Jezebel’s account is explicit on the uncertainty.

The political architecture is nevertheless conspicuous. The reported inquiry focuses on the period after Biden’s August 2021 military mandate, even though military personnel began receiving initial vaccine doses in December 2020, during the Trump administration. Operation Warp Speed put $18 billion in federal funding into vaccine research, development, and efforts to accelerate the timeline, according to the article. Pfizer and Moderna vaccines became available that same month. The timeline is summarized here.

That does not invalidate a properly designed safety review. It does make the selected frame an object of legitimate scrutiny. An administration can investigate adverse-event reports rigorously, or it can use the posture of investigation to manufacture a before-and-after morality play in which responsibility begins precisely when an opponent takes office. The first requires comparison groups, records, transparent methods, and a willingness to accept unwelcome answers. The second requires only a date line. In the current politics of leverage, the date line is doing rather a lot of work.